Analyst Price Targets — PLRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 12, 2026 1:20 pm | Yasmeen Rahimi | Piper Sandler | $3.00 | $1.37 | StreetInsider | Pliant Therapeutics (PLRX) PT Lowered to $3 at Piper Sandler |
| March 3, 2025 7:24 pm | — | Stifel Nicolaus | $3.00 | $1.38 | TheFly | Pliant Therapeutics downgraded to Hold from Buy at Stifel |
| March 3, 2025 5:25 pm | — | Leerink Partners | $2.00 | $1.38 | TheFly | Pliant Therapeutics downgraded to Market Perform from Outperform at Leerink |
| September 13, 2024 6:43 am | Ed Arce | H.C. Wainwright | $38.00 | $11.84 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Pliant Therapeutics (PLRX) |
| September 9, 2024 6:28 am | Faisal Khurshid | Leerink Partners | $33.00 | $12.87 | TheFly | Pliant Therapeutics assumed with an Outperform at Leerink |
| May 23, 2024 8:44 am | Yasmeen Rahimi | Piper Sandler | $40.00 | $13.85 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Pliant Therapeutics (PLRX) |
| May 7, 2024 8:29 am | Alex Thompson | Stifel Nicolaus | $32.00 | $13.91 | StreetInsider | Pliant Therapeutics (PLRX) PT Lowered to $32 at Stifel |
| May 7, 2024 7:42 am | Jeff Jones | Oppenheimer | $48.00 | $13.79 | StreetInsider | Pliant Therapeutics (PLRX) PT Raised to $48 at Oppenheimer |
| May 7, 2024 7:09 am | Ed Arce | H.C. Wainwright | $36.00 | $13.79 | StreetInsider | Pliant Therapeutics (PLRX) PT Lowered to $36 at H.C. Wainwright |
| May 7, 2024 6:19 am | Brian Abrahams | RBC Capital | $45.00 | $13.79 | StreetInsider | Pliant Therapeutics (PLRX) PT Lowered to $45 at RBC Capital |
Latest News for PLRX
Appointments bring global oncology drug development experience and deepen Board's operational and regulatory expertise
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.
First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed responses in checkpoint inhibitor-refractory solid tumors
SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the 2026 RBC Capital Markets Global Healthcare Conference. Bernard Coulie, M.D., Ph.D., Pliant's President and Chief Executive Officer, and Keith Cummings, M.D.,…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PLRX.
U.S. House Trading
No House trades found for PLRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.